Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors
4 December 2018 - - US-based biotechnology company GlycoMimetics, Inc. (NASDAQ: GLYC) has appointed Scott Jackson, former chief executive officer of Celator Pharmaceuticals, Inc., to its board of directors, the company said.

Jackson served as Celator's CEO and as a member of its board of directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc.

Jackson has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly and Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson and Johnson, Eximias Pharmaceutical and YM BioSciences. 

He holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Jackson presently serves on the board of directors of MacroGenics, Inc. and the board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society.

GlycoMimetics is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

The company's most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.

GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a company-sponsored Phase 3 trial in relapsed/refractory AML. 

The US Food and Drug Administration granted uproleselan breakthrough therapy designation for the treatment of adult AM) patients with relapsed/refractory disease.

GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.